Global Checkpoint Inhibitors for Treating Cancer Supply, Demand and Key Producers, 2026-2032
The global Checkpoint Inhibitors for Treating Cancer market size is expected to reach $ 105028 million by 2032, rising at a market growth of 7.4% CAGR during the forecast period (2026-2032).
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
This report studies the global Checkpoint Inhibitors for Treating Cancer production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Checkpoint Inhibitors for Treating Cancer and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Checkpoint Inhibitors for Treating Cancer that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Checkpoint Inhibitors for Treating Cancer total production and demand, 2021-2032, (K Units)
Global Checkpoint Inhibitors for Treating Cancer total production value, 2021-2032, (USD Million)
Global Checkpoint Inhibitors for Treating Cancer production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Checkpoint Inhibitors for Treating Cancer consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Checkpoint Inhibitors for Treating Cancer domestic production, consumption, key domestic manufacturers and share
Global Checkpoint Inhibitors for Treating Cancer production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Checkpoint Inhibitors for Treating Cancer production by Checkpoint Target, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Checkpoint Inhibitors for Treating Cancer production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Checkpoint Inhibitors for Treating Cancer market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., Bristol Myers Squibb, AstraZeneca, Roche, Regeneron Pharmaceuticals, GSK, Ono Pharmaceutical, BeOne Medicines, Merck KGaA, Innovent Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Checkpoint Inhibitors for Treating Cancer market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Checkpoint Target, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Checkpoint Inhibitors for Treating Cancer Market, By Region:
1. How big is the global Checkpoint Inhibitors for Treating Cancer market?
2. What is the demand of the global Checkpoint Inhibitors for Treating Cancer market?
3. What is the year over year growth of the global Checkpoint Inhibitors for Treating Cancer market?
4. What is the production and production value of the global Checkpoint Inhibitors for Treating Cancer market?
5. Who are the key producers in the global Checkpoint Inhibitors for Treating Cancer market?
6. What are the growth factors driving the market demand?
Checkpoint inhibitors for treating cancer are immuno-oncology medicines that block inhibitory immune-regulatory pathways, principally PD-1, PD-L1, CTLA-4 and LAG-3, allowing activated T cells to retain or recover their ability to identify and attack malignant cells. Checkpoint inhibitors includes commercial monoclonal antibodies, bispecific antibodies, single-domain antibody fusion products, fixed-dose antibody combinations and antibody-enzyme coformulations approved for cancer treatment.
Upstream of checkpoint inhibitors include mammalian cell lines, cell-culture media, single-use bioreactor assemblies, chromatography resins, filtration membranes, sterile excipients, glass vials, prefilled delivery components and cold-chain packaging. Manufacturing requires validated biologic production systems, aseptic fill-finish capacity, regulatory-grade analytical testing and continuous comparability control. Downstream customers consist primarily of oncology hospitals, specialist cancer centers, infusion clinics, public health systems, private insurers, government reimbursement agencies and national or regional pharmaceutical procurement platforms. Purchasing normally occurs through hospital formulary inclusion, national reimbursement negotiation, annual tendering, group purchasing contracts and long-term supply agreements. A representative producer gross margin is estimated at 79.0%, supported by biologic manufacturing barriers, regulatory exclusivity, extensive clinical evidence, broad approved labels, established physician familiarity and the high cost of switching treatment protocols.
In the current market, global production of Checkpoint inhibitors is around 27.5 million Units, with an average selling price of about 2,315 USD per Unit. Top 5 suppliers control approximately 91 percent of global revenue CR5. Merck leads through Keytruda and its subcutaneous formulation, followed by Bristol Myers Squibb with the Opdivo, Yervoy and Opdualag franchise. AstraZeneca, Roche and Regeneron form the remainder of the top five. North America remains the largest revenue market because of high net treatment prices and broad use in earlier treatment settings. Europe is the second-largest revenue region, while China has a substantially higher share of treatment volume than revenue because domestic PD-1, PD-L1 and bispecific products are sold at lower net prices following reimbursement negotiation. Japan is also material through Ono Pharmaceutical?s Opdivo franchise.
From 2026 through 2032, treatment volume is expected to increase faster than revenue as checkpoint therapy moves further into neoadjuvant, adjuvant and maintenance settings while average prices decline. Subcutaneous versions of established antibodies should reduce infusion-chair time and hospital administration costs, but they will also intensify life-cycle competition among incumbent suppliers. Chinese producers are expected to expand beyond the domestic market through international approvals, licensing agreements and lower-cost supply, particularly in lung, gastric, esophageal and hepatobiliary cancers. Bispecific products combining PD-1 with CTLA-4, VEGF or other immune pathways will increase their share, although only products demonstrating clear survival or safety advantages are likely to achieve broad reimbursement. Patent expiry around leading PD-1 franchises, biosimilar development, national price negotiation and payer restrictions will place sustained pressure on ASP. Competition will also come from antibody-drug conjugates, targeted therapies, radioligand treatments and biomarker-selected combination regimens.
This report studies the global Checkpoint Inhibitors for Treating Cancer production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Checkpoint Inhibitors for Treating Cancer and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Checkpoint Inhibitors for Treating Cancer that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Checkpoint Inhibitors for Treating Cancer total production and demand, 2021-2032, (K Units)
Global Checkpoint Inhibitors for Treating Cancer total production value, 2021-2032, (USD Million)
Global Checkpoint Inhibitors for Treating Cancer production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Checkpoint Inhibitors for Treating Cancer consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Checkpoint Inhibitors for Treating Cancer domestic production, consumption, key domestic manufacturers and share
Global Checkpoint Inhibitors for Treating Cancer production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Checkpoint Inhibitors for Treating Cancer production by Checkpoint Target, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Checkpoint Inhibitors for Treating Cancer production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Checkpoint Inhibitors for Treating Cancer market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., Bristol Myers Squibb, AstraZeneca, Roche, Regeneron Pharmaceuticals, GSK, Ono Pharmaceutical, BeOne Medicines, Merck KGaA, Innovent Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Checkpoint Inhibitors for Treating Cancer market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Checkpoint Target, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Checkpoint Inhibitors for Treating Cancer Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- PD-1 Single-target Inhibitor
- PD-L1 Single-target Inhibitor
- CTLA-4 Single-target Inhibitor
- PD-1/LAG-3 Combination
- PD-1/CTLA-4 Dual Product
- Other Checkpoint-containing Product
- Monoclonal Antibody
- Bispecific Antibody
- Fixed-dose Antibody Combination
- Antibody Enzyme Combination
- Intravenous Liquid Concentrate
- Intravenous Lyophilized Powder
- Subcutaneous Ready-to-use Injection
- Lung Cancer
- Gastrointestinal Cancer
- Genitourinary Cancer
- Hepatobiliary Cancer
- Gynecologic Cancer
- Skin Cancer
- Breast Cancer
- Head and Neck Cancer
- Hematologic Malignancy
- Other Solid Tumors
- Merck & Co.
- Bristol Myers Squibb
- AstraZeneca
- Roche
- Regeneron Pharmaceuticals
- GSK
- Ono Pharmaceutical
- BeOne Medicines
- Merck KGaA
- Innovent Biologics
- Jiangsu Hengrui Pharmaceuticals
- Shanghai Junshi Biosciences
- Akeso
- Shanghai Henlius Biotech
- Incyte
- Sino Biopharmaceutical
- BIOCAD
- Alphamab Oncology
1. How big is the global Checkpoint Inhibitors for Treating Cancer market?
2. What is the demand of the global Checkpoint Inhibitors for Treating Cancer market?
3. What is the year over year growth of the global Checkpoint Inhibitors for Treating Cancer market?
4. What is the production and production value of the global Checkpoint Inhibitors for Treating Cancer market?
5. Who are the key producers in the global Checkpoint Inhibitors for Treating Cancer market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Checkpoint Inhibitors for Treating Cancer Introduction
1.2 World Checkpoint Inhibitors for Treating Cancer Supply & Forecast
1.2.1 World Checkpoint Inhibitors for Treating Cancer Production Value (2021 & 2025 & 2032)
1.2.2 World Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.2.3 World Checkpoint Inhibitors for Treating Cancer Pricing Trends (2021-2032)
1.3 World Checkpoint Inhibitors for Treating Cancer Production by Region (Based on Production Site)
1.3.1 World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021-2032)
1.3.2 World Checkpoint Inhibitors for Treating Cancer Production by Region (2021-2032)
1.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2032)
1.3.4 North America Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.5 Europe Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.6 China Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.7 Japan Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Checkpoint Inhibitors for Treating Cancer Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Checkpoint Inhibitors for Treating Cancer Major Market Trends
2 DEMAND SUMMARY
2.1 World Checkpoint Inhibitors for Treating Cancer Demand (2021-2032)
2.2 World Checkpoint Inhibitors for Treating Cancer Consumption by Region
2.2.1 World Checkpoint Inhibitors for Treating Cancer Consumption by Region (2021-2026)
2.2.2 World Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Region (2027-2032)
2.3 United States Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.4 China Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.5 Europe Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.6 Japan Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.7 South Korea Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.8 ASEAN Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.9 India Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Checkpoint Inhibitors for Treating Cancer Production Value by Manufacturer (2021-2026)
3.2 World Checkpoint Inhibitors for Treating Cancer Production by Manufacturer (2021-2026)
3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026)
3.4 Checkpoint Inhibitors for Treating Cancer Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Checkpoint Inhibitors for Treating Cancer Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Checkpoint Inhibitors for Treating Cancer in 2025
3.5.3 Global Concentration Ratios (CR8) for Checkpoint Inhibitors for Treating Cancer in 2025
3.6 Checkpoint Inhibitors for Treating Cancer Market: Overall Company Footprint Analysis
3.6.1 Checkpoint Inhibitors for Treating Cancer Market: Region Footprint
3.6.2 Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
3.6.3 Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Comparison
4.1.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Comparison
4.2.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Comparison
4.3.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.4.3 United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
4.5 China Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share
4.5.1 China Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.5.3 China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
4.6 Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
5 MARKET ANALYSIS BY CHECKPOINT TARGET
5.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Checkpoint Target: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Checkpoint Target
5.2.1 PD-1 Single-target Inhibitor
5.2.2 PD-L1 Single-target Inhibitor
5.2.3 CTLA-4 Single-target Inhibitor
5.2.4 PD-1/LAG-3 Combination
5.2.5 PD-1/CTLA-4 Dual Product
5.2.6 Other Checkpoint-containing Product
5.3 Market Segment by Checkpoint Target
5.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2021-2032)
5.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2021-2032)
5.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032)
6 MARKET ANALYSIS BY MOLECULAR FORMAT
6.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Molecular Format: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Molecular Format
6.2.1 Monoclonal Antibody
6.2.2 Bispecific Antibody
6.2.3 Fixed-dose Antibody Combination
6.2.4 Antibody Enzyme Combination
6.3 Market Segment by Molecular Format
6.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2021-2032)
6.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2021-2032)
6.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2032)
7 MARKET ANALYSIS BY DOSAGE FORM
7.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dosage Form
7.2.1 Intravenous Liquid Concentrate
7.2.2 Intravenous Lyophilized Powder
7.2.3 Subcutaneous Ready-to-use Injection
7.3 Market Segment by Dosage Form
7.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2021-2032)
7.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2021-2032)
7.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Gastrointestinal Cancer
8.2.3 Genitourinary Cancer
8.2.4 Hepatobiliary Cancer
8.2.5 Gynecologic Cancer
8.2.6 Skin Cancer
8.2.7 Breast Cancer
8.2.8 Head and Neck Cancer
8.2.9 Hematologic Malignancy
8.3 Market Segment by Application
8.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Application (2021-2032)
8.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2021-2032)
8.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Merck & Co.
9.1.1 Merck & Co. Details
9.1.2 Merck & Co. Major Business
9.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
9.1.4 Merck & Co. Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Merck & Co. Recent Developments/Updates
9.1.6 Merck & Co. Competitive Strengths & Weaknesses
9.2 Bristol Myers Squibb
9.2.1 Bristol Myers Squibb Details
9.2.2 Bristol Myers Squibb Major Business
9.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
9.2.4 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Bristol Myers Squibb Recent Developments/Updates
9.2.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.3 AstraZeneca
9.3.1 AstraZeneca Details
9.3.2 AstraZeneca Major Business
9.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
9.3.4 AstraZeneca Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 AstraZeneca Recent Developments/Updates
9.3.6 AstraZeneca Competitive Strengths & Weaknesses
9.4 Roche
9.4.1 Roche Details
9.4.2 Roche Major Business
9.4.3 Roche Checkpoint Inhibitors for Treating Cancer Product and Services
9.4.4 Roche Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Roche Recent Developments/Updates
9.4.6 Roche Competitive Strengths & Weaknesses
9.5 Regeneron Pharmaceuticals
9.5.1 Regeneron Pharmaceuticals Details
9.5.2 Regeneron Pharmaceuticals Major Business
9.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
9.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.5.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.6 GSK
9.6.1 GSK Details
9.6.2 GSK Major Business
9.6.3 GSK Checkpoint Inhibitors for Treating Cancer Product and Services
9.6.4 GSK Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 GSK Recent Developments/Updates
9.6.6 GSK Competitive Strengths & Weaknesses
9.7 Ono Pharmaceutical
9.7.1 Ono Pharmaceutical Details
9.7.2 Ono Pharmaceutical Major Business
9.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
9.7.4 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Ono Pharmaceutical Recent Developments/Updates
9.7.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.8 BeOne Medicines
9.8.1 BeOne Medicines Details
9.8.2 BeOne Medicines Major Business
9.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
9.8.4 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 BeOne Medicines Recent Developments/Updates
9.8.6 BeOne Medicines Competitive Strengths & Weaknesses
9.9 Merck KGaA
9.9.1 Merck KGaA Details
9.9.2 Merck KGaA Major Business
9.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
9.9.4 Merck KGaA Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Merck KGaA Recent Developments/Updates
9.9.6 Merck KGaA Competitive Strengths & Weaknesses
9.10 Innovent Biologics
9.10.1 Innovent Biologics Details
9.10.2 Innovent Biologics Major Business
9.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
9.10.4 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Innovent Biologics Recent Developments/Updates
9.10.6 Innovent Biologics Competitive Strengths & Weaknesses
9.11 Jiangsu Hengrui Pharmaceuticals
9.11.1 Jiangsu Hengrui Pharmaceuticals Details
9.11.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
9.11.4 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.11.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.12 Shanghai Junshi Biosciences
9.12.1 Shanghai Junshi Biosciences Details
9.12.2 Shanghai Junshi Biosciences Major Business
9.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
9.12.4 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Shanghai Junshi Biosciences Recent Developments/Updates
9.12.6 Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
9.13 Akeso
9.13.1 Akeso Details
9.13.2 Akeso Major Business
9.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
9.13.4 Akeso Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Akeso Recent Developments/Updates
9.13.6 Akeso Competitive Strengths & Weaknesses
9.14 Shanghai Henlius Biotech
9.14.1 Shanghai Henlius Biotech Details
9.14.2 Shanghai Henlius Biotech Major Business
9.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
9.14.4 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Shanghai Henlius Biotech Recent Developments/Updates
9.14.6 Shanghai Henlius Biotech Competitive Strengths & Weaknesses
9.15 Incyte
9.15.1 Incyte Details
9.15.2 Incyte Major Business
9.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
9.15.4 Incyte Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Incyte Recent Developments/Updates
9.15.6 Incyte Competitive Strengths & Weaknesses
9.16 Sino Biopharmaceutical
9.16.1 Sino Biopharmaceutical Details
9.16.2 Sino Biopharmaceutical Major Business
9.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
9.16.4 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Sino Biopharmaceutical Recent Developments/Updates
9.16.6 Sino Biopharmaceutical Competitive Strengths & Weaknesses
9.17 BIOCAD
9.17.1 BIOCAD Details
9.17.2 BIOCAD Major Business
9.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
9.17.4 BIOCAD Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 BIOCAD Recent Developments/Updates
9.17.6 BIOCAD Competitive Strengths & Weaknesses
9.18 Alphamab Oncology
9.18.1 Alphamab Oncology Details
9.18.2 Alphamab Oncology Major Business
9.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
9.18.4 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Alphamab Oncology Recent Developments/Updates
9.18.6 Alphamab Oncology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Checkpoint Inhibitors for Treating Cancer Industry Chain
10.2 Checkpoint Inhibitors for Treating Cancer Upstream Analysis
10.2.1 Checkpoint Inhibitors for Treating Cancer Core Raw Materials
10.2.2 Main Manufacturers of Checkpoint Inhibitors for Treating Cancer Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Checkpoint Inhibitors for Treating Cancer Production Mode
10.6 Checkpoint Inhibitors for Treating Cancer Procurement Model
10.7 Checkpoint Inhibitors for Treating Cancer Industry Sales Model and Sales Channels
10.7.1 Checkpoint Inhibitors for Treating Cancer Sales Model
10.7.2 Checkpoint Inhibitors for Treating Cancer Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Checkpoint Inhibitors for Treating Cancer Introduction
1.2 World Checkpoint Inhibitors for Treating Cancer Supply & Forecast
1.2.1 World Checkpoint Inhibitors for Treating Cancer Production Value (2021 & 2025 & 2032)
1.2.2 World Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.2.3 World Checkpoint Inhibitors for Treating Cancer Pricing Trends (2021-2032)
1.3 World Checkpoint Inhibitors for Treating Cancer Production by Region (Based on Production Site)
1.3.1 World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021-2032)
1.3.2 World Checkpoint Inhibitors for Treating Cancer Production by Region (2021-2032)
1.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2032)
1.3.4 North America Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.5 Europe Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.6 China Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.3.7 Japan Checkpoint Inhibitors for Treating Cancer Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Checkpoint Inhibitors for Treating Cancer Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Checkpoint Inhibitors for Treating Cancer Major Market Trends
2 DEMAND SUMMARY
2.1 World Checkpoint Inhibitors for Treating Cancer Demand (2021-2032)
2.2 World Checkpoint Inhibitors for Treating Cancer Consumption by Region
2.2.1 World Checkpoint Inhibitors for Treating Cancer Consumption by Region (2021-2026)
2.2.2 World Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Region (2027-2032)
2.3 United States Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.4 China Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.5 Europe Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.6 Japan Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.7 South Korea Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.8 ASEAN Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
2.9 India Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Checkpoint Inhibitors for Treating Cancer Production Value by Manufacturer (2021-2026)
3.2 World Checkpoint Inhibitors for Treating Cancer Production by Manufacturer (2021-2026)
3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026)
3.4 Checkpoint Inhibitors for Treating Cancer Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Checkpoint Inhibitors for Treating Cancer Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Checkpoint Inhibitors for Treating Cancer in 2025
3.5.3 Global Concentration Ratios (CR8) for Checkpoint Inhibitors for Treating Cancer in 2025
3.6 Checkpoint Inhibitors for Treating Cancer Market: Overall Company Footprint Analysis
3.6.1 Checkpoint Inhibitors for Treating Cancer Market: Region Footprint
3.6.2 Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
3.6.3 Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Comparison
4.1.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Comparison
4.2.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Comparison
4.3.1 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.4.3 United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
4.5 China Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share
4.5.1 China Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.5.3 China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
4.6 Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026)
5 MARKET ANALYSIS BY CHECKPOINT TARGET
5.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Checkpoint Target: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Checkpoint Target
5.2.1 PD-1 Single-target Inhibitor
5.2.2 PD-L1 Single-target Inhibitor
5.2.3 CTLA-4 Single-target Inhibitor
5.2.4 PD-1/LAG-3 Combination
5.2.5 PD-1/CTLA-4 Dual Product
5.2.6 Other Checkpoint-containing Product
5.3 Market Segment by Checkpoint Target
5.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2021-2032)
5.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2021-2032)
5.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032)
6 MARKET ANALYSIS BY MOLECULAR FORMAT
6.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Molecular Format: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Molecular Format
6.2.1 Monoclonal Antibody
6.2.2 Bispecific Antibody
6.2.3 Fixed-dose Antibody Combination
6.2.4 Antibody Enzyme Combination
6.3 Market Segment by Molecular Format
6.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2021-2032)
6.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2021-2032)
6.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2032)
7 MARKET ANALYSIS BY DOSAGE FORM
7.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dosage Form
7.2.1 Intravenous Liquid Concentrate
7.2.2 Intravenous Lyophilized Powder
7.2.3 Subcutaneous Ready-to-use Injection
7.3 Market Segment by Dosage Form
7.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2021-2032)
7.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2021-2032)
7.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Checkpoint Inhibitors for Treating Cancer Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Gastrointestinal Cancer
8.2.3 Genitourinary Cancer
8.2.4 Hepatobiliary Cancer
8.2.5 Gynecologic Cancer
8.2.6 Skin Cancer
8.2.7 Breast Cancer
8.2.8 Head and Neck Cancer
8.2.9 Hematologic Malignancy
8.3 Market Segment by Application
8.3.1 World Checkpoint Inhibitors for Treating Cancer Production by Application (2021-2032)
8.3.2 World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2021-2032)
8.3.3 World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Merck & Co.
9.1.1 Merck & Co. Details
9.1.2 Merck & Co. Major Business
9.1.3 Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
9.1.4 Merck & Co. Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Merck & Co. Recent Developments/Updates
9.1.6 Merck & Co. Competitive Strengths & Weaknesses
9.2 Bristol Myers Squibb
9.2.1 Bristol Myers Squibb Details
9.2.2 Bristol Myers Squibb Major Business
9.2.3 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
9.2.4 Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Bristol Myers Squibb Recent Developments/Updates
9.2.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.3 AstraZeneca
9.3.1 AstraZeneca Details
9.3.2 AstraZeneca Major Business
9.3.3 AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
9.3.4 AstraZeneca Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 AstraZeneca Recent Developments/Updates
9.3.6 AstraZeneca Competitive Strengths & Weaknesses
9.4 Roche
9.4.1 Roche Details
9.4.2 Roche Major Business
9.4.3 Roche Checkpoint Inhibitors for Treating Cancer Product and Services
9.4.4 Roche Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Roche Recent Developments/Updates
9.4.6 Roche Competitive Strengths & Weaknesses
9.5 Regeneron Pharmaceuticals
9.5.1 Regeneron Pharmaceuticals Details
9.5.2 Regeneron Pharmaceuticals Major Business
9.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
9.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.5.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.6 GSK
9.6.1 GSK Details
9.6.2 GSK Major Business
9.6.3 GSK Checkpoint Inhibitors for Treating Cancer Product and Services
9.6.4 GSK Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 GSK Recent Developments/Updates
9.6.6 GSK Competitive Strengths & Weaknesses
9.7 Ono Pharmaceutical
9.7.1 Ono Pharmaceutical Details
9.7.2 Ono Pharmaceutical Major Business
9.7.3 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
9.7.4 Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Ono Pharmaceutical Recent Developments/Updates
9.7.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.8 BeOne Medicines
9.8.1 BeOne Medicines Details
9.8.2 BeOne Medicines Major Business
9.8.3 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
9.8.4 BeOne Medicines Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 BeOne Medicines Recent Developments/Updates
9.8.6 BeOne Medicines Competitive Strengths & Weaknesses
9.9 Merck KGaA
9.9.1 Merck KGaA Details
9.9.2 Merck KGaA Major Business
9.9.3 Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
9.9.4 Merck KGaA Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Merck KGaA Recent Developments/Updates
9.9.6 Merck KGaA Competitive Strengths & Weaknesses
9.10 Innovent Biologics
9.10.1 Innovent Biologics Details
9.10.2 Innovent Biologics Major Business
9.10.3 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
9.10.4 Innovent Biologics Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Innovent Biologics Recent Developments/Updates
9.10.6 Innovent Biologics Competitive Strengths & Weaknesses
9.11 Jiangsu Hengrui Pharmaceuticals
9.11.1 Jiangsu Hengrui Pharmaceuticals Details
9.11.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.11.3 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
9.11.4 Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.11.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.12 Shanghai Junshi Biosciences
9.12.1 Shanghai Junshi Biosciences Details
9.12.2 Shanghai Junshi Biosciences Major Business
9.12.3 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
9.12.4 Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Shanghai Junshi Biosciences Recent Developments/Updates
9.12.6 Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
9.13 Akeso
9.13.1 Akeso Details
9.13.2 Akeso Major Business
9.13.3 Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
9.13.4 Akeso Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Akeso Recent Developments/Updates
9.13.6 Akeso Competitive Strengths & Weaknesses
9.14 Shanghai Henlius Biotech
9.14.1 Shanghai Henlius Biotech Details
9.14.2 Shanghai Henlius Biotech Major Business
9.14.3 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
9.14.4 Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Shanghai Henlius Biotech Recent Developments/Updates
9.14.6 Shanghai Henlius Biotech Competitive Strengths & Weaknesses
9.15 Incyte
9.15.1 Incyte Details
9.15.2 Incyte Major Business
9.15.3 Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
9.15.4 Incyte Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Incyte Recent Developments/Updates
9.15.6 Incyte Competitive Strengths & Weaknesses
9.16 Sino Biopharmaceutical
9.16.1 Sino Biopharmaceutical Details
9.16.2 Sino Biopharmaceutical Major Business
9.16.3 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
9.16.4 Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Sino Biopharmaceutical Recent Developments/Updates
9.16.6 Sino Biopharmaceutical Competitive Strengths & Weaknesses
9.17 BIOCAD
9.17.1 BIOCAD Details
9.17.2 BIOCAD Major Business
9.17.3 BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
9.17.4 BIOCAD Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 BIOCAD Recent Developments/Updates
9.17.6 BIOCAD Competitive Strengths & Weaknesses
9.18 Alphamab Oncology
9.18.1 Alphamab Oncology Details
9.18.2 Alphamab Oncology Major Business
9.18.3 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
9.18.4 Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Alphamab Oncology Recent Developments/Updates
9.18.6 Alphamab Oncology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Checkpoint Inhibitors for Treating Cancer Industry Chain
10.2 Checkpoint Inhibitors for Treating Cancer Upstream Analysis
10.2.1 Checkpoint Inhibitors for Treating Cancer Core Raw Materials
10.2.2 Main Manufacturers of Checkpoint Inhibitors for Treating Cancer Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Checkpoint Inhibitors for Treating Cancer Production Mode
10.6 Checkpoint Inhibitors for Treating Cancer Procurement Model
10.7 Checkpoint Inhibitors for Treating Cancer Industry Sales Model and Sales Channels
10.7.1 Checkpoint Inhibitors for Treating Cancer Sales Model
10.7.2 Checkpoint Inhibitors for Treating Cancer Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021-2026) & (USD Million)
Table 3. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2027-2032) & (USD Million)
Table 4. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2021-2026)
Table 5. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2027-2032)
Table 6. World Checkpoint Inhibitors for Treating Cancer Production by Region (2021-2026) & (K Units)
Table 7. World Checkpoint Inhibitors for Treating Cancer Production by Region (2027-2032) & (K Units)
Table 8. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2021-2026)
Table 9. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2027-2032)
Table 10. World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Checkpoint Inhibitors for Treating Cancer Major Market Trends
Table 13. World Checkpoint Inhibitors for Treating Cancer Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Checkpoint Inhibitors for Treating Cancer Consumption by Region (2021-2026) & (K Units)
Table 15. World Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Checkpoint Inhibitors for Treating Cancer Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Checkpoint Inhibitors for Treating Cancer Producers in 2025
Table 18. World Checkpoint Inhibitors for Treating Cancer Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Checkpoint Inhibitors for Treating Cancer Producers in 2025
Table 20. World Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Company Evaluation Quadrant
Table 22. World Checkpoint Inhibitors for Treating Cancer Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Checkpoint Inhibitors for Treating Cancer Production Site of Key Manufacturer
Table 24. Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
Table 25. Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
Table 26. Checkpoint Inhibitors for Treating Cancer Competitive Factors
Table 27. Checkpoint Inhibitors for Treating Cancer New Entrant and Capacity Expansion Plans
Table 28. Checkpoint Inhibitors for Treating Cancer Mergers & Acquisitions Activity
Table 29. United States VS China Checkpoint Inhibitors for Treating Cancer Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Checkpoint Inhibitors for Treating Cancer Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Checkpoint Inhibitors for Treating Cancer Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 37. China Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 42. Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 47. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Table 48. World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2021-2026) & (K Units)
Table 49. World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2027-2032) & (K Units)
Table 50. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2021-2026) & (USD Million)
Table 51. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2027-2032) & (USD Million)
Table 52. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 53. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2027-2032) & (US$/Unit)
Table 54. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Table 55. World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2021-2026) & (K Units)
Table 56. World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2027-2032) & (K Units)
Table 57. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2021-2026) & (USD Million)
Table 58. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2027-2032) & (USD Million)
Table 59. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2026) & (US$/Unit)
Table 60. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2027-2032) & (US$/Unit)
Table 61. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 62. World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2021-2026) & (K Units)
Table 63. World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2027-2032) & (K Units)
Table 64. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2021-2026) & (USD Million)
Table 65. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2027-2032) & (USD Million)
Table 66. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 67. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 68. World Checkpoint Inhibitors for Treating Cancer Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Checkpoint Inhibitors for Treating Cancer Production by Application (2021-2026) & (K Units)
Table 70. World Checkpoint Inhibitors for Treating Cancer Production by Application (2027-2032) & (K Units)
Table 71. World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2021-2026) & (USD Million)
Table 72. World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2027-2032) & (USD Million)
Table 73. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 76. Merck & Co. Major Business
Table 77. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
Table 78. Merck & Co. Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Merck & Co. Recent Developments/Updates
Table 80. Merck & Co. Competitive Strengths & Weaknesses
Table 81. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 82. Bristol Myers Squibb Major Business
Table 83. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
Table 84. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Bristol Myers Squibb Recent Developments/Updates
Table 86. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 87. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 88. AstraZeneca Major Business
Table 89. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
Table 90. AstraZeneca Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. AstraZeneca Recent Developments/Updates
Table 92. AstraZeneca Competitive Strengths & Weaknesses
Table 93. Roche Basic Information, Manufacturing Base and Competitors
Table 94. Roche Major Business
Table 95. Roche Checkpoint Inhibitors for Treating Cancer Product and Services
Table 96. Roche Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Roche Recent Developments/Updates
Table 98. Roche Competitive Strengths & Weaknesses
Table 99. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 100. Regeneron Pharmaceuticals Major Business
Table 101. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 102. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Regeneron Pharmaceuticals Recent Developments/Updates
Table 104. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 105. GSK Basic Information, Manufacturing Base and Competitors
Table 106. GSK Major Business
Table 107. GSK Checkpoint Inhibitors for Treating Cancer Product and Services
Table 108. GSK Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. GSK Recent Developments/Updates
Table 110. GSK Competitive Strengths & Weaknesses
Table 111. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Ono Pharmaceutical Major Business
Table 113. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 114. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Ono Pharmaceutical Recent Developments/Updates
Table 116. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 117. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 118. BeOne Medicines Major Business
Table 119. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
Table 120. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. BeOne Medicines Recent Developments/Updates
Table 122. BeOne Medicines Competitive Strengths & Weaknesses
Table 123. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 124. Merck KGaA Major Business
Table 125. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
Table 126. Merck KGaA Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Merck KGaA Recent Developments/Updates
Table 128. Merck KGaA Competitive Strengths & Weaknesses
Table 129. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 130. Innovent Biologics Major Business
Table 131. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
Table 132. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Innovent Biologics Recent Developments/Updates
Table 134. Innovent Biologics Competitive Strengths & Weaknesses
Table 135. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 136. Jiangsu Hengrui Pharmaceuticals Major Business
Table 137. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 138. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 140. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 141. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 142. Shanghai Junshi Biosciences Major Business
Table 143. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
Table 144. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Shanghai Junshi Biosciences Recent Developments/Updates
Table 146. Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
Table 147. Akeso Basic Information, Manufacturing Base and Competitors
Table 148. Akeso Major Business
Table 149. Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
Table 150. Akeso Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Akeso Recent Developments/Updates
Table 152. Akeso Competitive Strengths & Weaknesses
Table 153. Shanghai Henlius Biotech Basic Information, Manufacturing Base and Competitors
Table 154. Shanghai Henlius Biotech Major Business
Table 155. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
Table 156. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Shanghai Henlius Biotech Recent Developments/Updates
Table 158. Shanghai Henlius Biotech Competitive Strengths & Weaknesses
Table 159. Incyte Basic Information, Manufacturing Base and Competitors
Table 160. Incyte Major Business
Table 161. Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
Table 162. Incyte Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Incyte Recent Developments/Updates
Table 164. Incyte Competitive Strengths & Weaknesses
Table 165. Sino Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 166. Sino Biopharmaceutical Major Business
Table 167. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 168. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Sino Biopharmaceutical Recent Developments/Updates
Table 170. Sino Biopharmaceutical Competitive Strengths & Weaknesses
Table 171. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 172. BIOCAD Major Business
Table 173. BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
Table 174. BIOCAD Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. BIOCAD Recent Developments/Updates
Table 176. BIOCAD Competitive Strengths & Weaknesses
Table 177. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 178. Alphamab Oncology Major Business
Table 179. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
Table 180. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Alphamab Oncology Recent Developments/Updates
Table 182. Alphamab Oncology Competitive Strengths & Weaknesses
Table 183. Global Key Players of Checkpoint Inhibitors for Treating Cancer Upstream (Raw Materials)
Table 184. Global Checkpoint Inhibitors for Treating Cancer Typical Customers
Table 185. Checkpoint Inhibitors for Treating Cancer Typical Distributors
Table 1. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2021-2026) & (USD Million)
Table 3. World Checkpoint Inhibitors for Treating Cancer Production Value by Region (2027-2032) & (USD Million)
Table 4. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2021-2026)
Table 5. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2027-2032)
Table 6. World Checkpoint Inhibitors for Treating Cancer Production by Region (2021-2026) & (K Units)
Table 7. World Checkpoint Inhibitors for Treating Cancer Production by Region (2027-2032) & (K Units)
Table 8. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2021-2026)
Table 9. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2027-2032)
Table 10. World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Checkpoint Inhibitors for Treating Cancer Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Checkpoint Inhibitors for Treating Cancer Major Market Trends
Table 13. World Checkpoint Inhibitors for Treating Cancer Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Checkpoint Inhibitors for Treating Cancer Consumption by Region (2021-2026) & (K Units)
Table 15. World Checkpoint Inhibitors for Treating Cancer Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Checkpoint Inhibitors for Treating Cancer Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Checkpoint Inhibitors for Treating Cancer Producers in 2025
Table 18. World Checkpoint Inhibitors for Treating Cancer Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Checkpoint Inhibitors for Treating Cancer Producers in 2025
Table 20. World Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Company Evaluation Quadrant
Table 22. World Checkpoint Inhibitors for Treating Cancer Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Checkpoint Inhibitors for Treating Cancer Production Site of Key Manufacturer
Table 24. Checkpoint Inhibitors for Treating Cancer Market: Company Product Type Footprint
Table 25. Checkpoint Inhibitors for Treating Cancer Market: Company Product Application Footprint
Table 26. Checkpoint Inhibitors for Treating Cancer Competitive Factors
Table 27. Checkpoint Inhibitors for Treating Cancer New Entrant and Capacity Expansion Plans
Table 28. Checkpoint Inhibitors for Treating Cancer Mergers & Acquisitions Activity
Table 29. United States VS China Checkpoint Inhibitors for Treating Cancer Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Checkpoint Inhibitors for Treating Cancer Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Checkpoint Inhibitors for Treating Cancer Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 37. China Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 42. Rest of World Based Checkpoint Inhibitors for Treating Cancer Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share (2021-2026)
Table 47. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Table 48. World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2021-2026) & (K Units)
Table 49. World Checkpoint Inhibitors for Treating Cancer Production by Checkpoint Target (2027-2032) & (K Units)
Table 50. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2021-2026) & (USD Million)
Table 51. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target (2027-2032) & (USD Million)
Table 52. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2026) & (US$/Unit)
Table 53. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2027-2032) & (US$/Unit)
Table 54. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Table 55. World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2021-2026) & (K Units)
Table 56. World Checkpoint Inhibitors for Treating Cancer Production by Molecular Format (2027-2032) & (K Units)
Table 57. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2021-2026) & (USD Million)
Table 58. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format (2027-2032) & (USD Million)
Table 59. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2026) & (US$/Unit)
Table 60. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2027-2032) & (US$/Unit)
Table 61. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 62. World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2021-2026) & (K Units)
Table 63. World Checkpoint Inhibitors for Treating Cancer Production by Dosage Form (2027-2032) & (K Units)
Table 64. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2021-2026) & (USD Million)
Table 65. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form (2027-2032) & (USD Million)
Table 66. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 67. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 68. World Checkpoint Inhibitors for Treating Cancer Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Checkpoint Inhibitors for Treating Cancer Production by Application (2021-2026) & (K Units)
Table 70. World Checkpoint Inhibitors for Treating Cancer Production by Application (2027-2032) & (K Units)
Table 71. World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2021-2026) & (USD Million)
Table 72. World Checkpoint Inhibitors for Treating Cancer Production Value by Application (2027-2032) & (USD Million)
Table 73. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 76. Merck & Co. Major Business
Table 77. Merck & Co. Checkpoint Inhibitors for Treating Cancer Product and Services
Table 78. Merck & Co. Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Merck & Co. Recent Developments/Updates
Table 80. Merck & Co. Competitive Strengths & Weaknesses
Table 81. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 82. Bristol Myers Squibb Major Business
Table 83. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Product and Services
Table 84. Bristol Myers Squibb Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Bristol Myers Squibb Recent Developments/Updates
Table 86. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 87. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 88. AstraZeneca Major Business
Table 89. AstraZeneca Checkpoint Inhibitors for Treating Cancer Product and Services
Table 90. AstraZeneca Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. AstraZeneca Recent Developments/Updates
Table 92. AstraZeneca Competitive Strengths & Weaknesses
Table 93. Roche Basic Information, Manufacturing Base and Competitors
Table 94. Roche Major Business
Table 95. Roche Checkpoint Inhibitors for Treating Cancer Product and Services
Table 96. Roche Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Roche Recent Developments/Updates
Table 98. Roche Competitive Strengths & Weaknesses
Table 99. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 100. Regeneron Pharmaceuticals Major Business
Table 101. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 102. Regeneron Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Regeneron Pharmaceuticals Recent Developments/Updates
Table 104. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 105. GSK Basic Information, Manufacturing Base and Competitors
Table 106. GSK Major Business
Table 107. GSK Checkpoint Inhibitors for Treating Cancer Product and Services
Table 108. GSK Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. GSK Recent Developments/Updates
Table 110. GSK Competitive Strengths & Weaknesses
Table 111. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Ono Pharmaceutical Major Business
Table 113. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 114. Ono Pharmaceutical Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Ono Pharmaceutical Recent Developments/Updates
Table 116. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 117. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 118. BeOne Medicines Major Business
Table 119. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Product and Services
Table 120. BeOne Medicines Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. BeOne Medicines Recent Developments/Updates
Table 122. BeOne Medicines Competitive Strengths & Weaknesses
Table 123. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 124. Merck KGaA Major Business
Table 125. Merck KGaA Checkpoint Inhibitors for Treating Cancer Product and Services
Table 126. Merck KGaA Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Merck KGaA Recent Developments/Updates
Table 128. Merck KGaA Competitive Strengths & Weaknesses
Table 129. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 130. Innovent Biologics Major Business
Table 131. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Product and Services
Table 132. Innovent Biologics Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Innovent Biologics Recent Developments/Updates
Table 134. Innovent Biologics Competitive Strengths & Weaknesses
Table 135. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 136. Jiangsu Hengrui Pharmaceuticals Major Business
Table 137. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Product and Services
Table 138. Jiangsu Hengrui Pharmaceuticals Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 140. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 141. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 142. Shanghai Junshi Biosciences Major Business
Table 143. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Product and Services
Table 144. Shanghai Junshi Biosciences Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Shanghai Junshi Biosciences Recent Developments/Updates
Table 146. Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
Table 147. Akeso Basic Information, Manufacturing Base and Competitors
Table 148. Akeso Major Business
Table 149. Akeso Checkpoint Inhibitors for Treating Cancer Product and Services
Table 150. Akeso Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Akeso Recent Developments/Updates
Table 152. Akeso Competitive Strengths & Weaknesses
Table 153. Shanghai Henlius Biotech Basic Information, Manufacturing Base and Competitors
Table 154. Shanghai Henlius Biotech Major Business
Table 155. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Product and Services
Table 156. Shanghai Henlius Biotech Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Shanghai Henlius Biotech Recent Developments/Updates
Table 158. Shanghai Henlius Biotech Competitive Strengths & Weaknesses
Table 159. Incyte Basic Information, Manufacturing Base and Competitors
Table 160. Incyte Major Business
Table 161. Incyte Checkpoint Inhibitors for Treating Cancer Product and Services
Table 162. Incyte Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Incyte Recent Developments/Updates
Table 164. Incyte Competitive Strengths & Weaknesses
Table 165. Sino Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 166. Sino Biopharmaceutical Major Business
Table 167. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Product and Services
Table 168. Sino Biopharmaceutical Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Sino Biopharmaceutical Recent Developments/Updates
Table 170. Sino Biopharmaceutical Competitive Strengths & Weaknesses
Table 171. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 172. BIOCAD Major Business
Table 173. BIOCAD Checkpoint Inhibitors for Treating Cancer Product and Services
Table 174. BIOCAD Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. BIOCAD Recent Developments/Updates
Table 176. BIOCAD Competitive Strengths & Weaknesses
Table 177. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 178. Alphamab Oncology Major Business
Table 179. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Product and Services
Table 180. Alphamab Oncology Checkpoint Inhibitors for Treating Cancer Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Alphamab Oncology Recent Developments/Updates
Table 182. Alphamab Oncology Competitive Strengths & Weaknesses
Table 183. Global Key Players of Checkpoint Inhibitors for Treating Cancer Upstream (Raw Materials)
Table 184. Global Checkpoint Inhibitors for Treating Cancer Typical Customers
Table 185. Checkpoint Inhibitors for Treating Cancer Typical Distributors
LIST OF FIGURES
Figure 1. Checkpoint Inhibitors for Treating Cancer Picture
Figure 2. World Checkpoint Inhibitors for Treating Cancer Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Checkpoint Inhibitors for Treating Cancer Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 5. World Checkpoint Inhibitors for Treating Cancer Average Price (2021-2032) & (US$/Unit)
Figure 6. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2021-2032)
Figure 7. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2021-2032)
Figure 8. North America Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 9. Europe Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 10. China Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 11. Japan Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 12. Checkpoint Inhibitors for Treating Cancer Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 15. World Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Region (2021-2032)
Figure 16. United States Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 17. China Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 18. Europe Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 19. Japan Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 20. South Korea Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 22. India Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Checkpoint Inhibitors for Treating Cancer Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Checkpoint Inhibitors for Treating Cancer Markets in 2025
Figure 26. United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Checkpoint Inhibitors for Treating Cancer Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 30. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 32. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Figure 33. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Checkpoint Target in 2025
Figure 34. PD-1 Single-target Inhibitor
Figure 35. PD-L1 Single-target Inhibitor
Figure 36. CTLA-4 Single-target Inhibitor
Figure 37. PD-1/LAG-3 Combination
Figure 38. PD-1/CTLA-4 Dual Product
Figure 39. Other Checkpoint-containing Product
Figure 40. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Checkpoint Target (2021-2032)
Figure 41. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Checkpoint Target (2021-2032)
Figure 42. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032) & (US$/Unit)
Figure 43. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Figure 44. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Molecular Format in 2025
Figure 45. Monoclonal Antibody
Figure 46. Bispecific Antibody
Figure 47. Fixed-dose Antibody Combination
Figure 48. Antibody Enzyme Combination
Figure 49. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Molecular Format (2021-2032)
Figure 50. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Molecular Format (2021-2032)
Figure 51. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2032) & (US$/Unit)
Figure 52. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 53. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Dosage Form in 2025
Figure 54. Intravenous Liquid Concentrate
Figure 55. Intravenous Lyophilized Powder
Figure 56. Subcutaneous Ready-to-use Injection
Figure 57. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Dosage Form (2021-2032)
Figure 58. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Dosage Form (2021-2032)
Figure 59. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 60. World Checkpoint Inhibitors for Treating Cancer Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 61. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Application in 2025
Figure 62. Lung Cancer
Figure 63. Gastrointestinal Cancer
Figure 64. Genitourinary Cancer
Figure 65. Hepatobiliary Cancer
Figure 66. Gynecologic Cancer
Figure 67. Skin Cancer
Figure 68. Breast Cancer
Figure 69. Head and Neck Cancer
Figure 70. Head and Neck Cancer
Figure 71. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Application (2021-2032)
Figure 72. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Application (2021-2032)
Figure 73. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032) & (US$/Unit)
Figure 74. Checkpoint Inhibitors for Treating Cancer Industry Chain
Figure 75. Checkpoint Inhibitors for Treating Cancer Procurement Model
Figure 76. Checkpoint Inhibitors for Treating Cancer Sales Model
Figure 77. Checkpoint Inhibitors for Treating Cancer Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Checkpoint Inhibitors for Treating Cancer Picture
Figure 2. World Checkpoint Inhibitors for Treating Cancer Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Checkpoint Inhibitors for Treating Cancer Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 5. World Checkpoint Inhibitors for Treating Cancer Average Price (2021-2032) & (US$/Unit)
Figure 6. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Region (2021-2032)
Figure 7. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Region (2021-2032)
Figure 8. North America Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 9. Europe Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 10. China Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 11. Japan Checkpoint Inhibitors for Treating Cancer Production (2021-2032) & (K Units)
Figure 12. Checkpoint Inhibitors for Treating Cancer Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 15. World Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Region (2021-2032)
Figure 16. United States Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 17. China Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 18. Europe Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 19. Japan Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 20. South Korea Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 22. India Checkpoint Inhibitors for Treating Cancer Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Checkpoint Inhibitors for Treating Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Checkpoint Inhibitors for Treating Cancer Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Checkpoint Inhibitors for Treating Cancer Markets in 2025
Figure 26. United States VS China: Checkpoint Inhibitors for Treating Cancer Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Checkpoint Inhibitors for Treating Cancer Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Checkpoint Inhibitors for Treating Cancer Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 30. China Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Checkpoint Inhibitors for Treating Cancer Production Market Share 2025
Figure 32. World Checkpoint Inhibitors for Treating Cancer Production Value by Checkpoint Target, (USD Million), 2021 & 2025 & 2032
Figure 33. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Checkpoint Target in 2025
Figure 34. PD-1 Single-target Inhibitor
Figure 35. PD-L1 Single-target Inhibitor
Figure 36. CTLA-4 Single-target Inhibitor
Figure 37. PD-1/LAG-3 Combination
Figure 38. PD-1/CTLA-4 Dual Product
Figure 39. Other Checkpoint-containing Product
Figure 40. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Checkpoint Target (2021-2032)
Figure 41. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Checkpoint Target (2021-2032)
Figure 42. World Checkpoint Inhibitors for Treating Cancer Average Price by Checkpoint Target (2021-2032) & (US$/Unit)
Figure 43. World Checkpoint Inhibitors for Treating Cancer Production Value by Molecular Format, (USD Million), 2021 & 2025 & 2032
Figure 44. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Molecular Format in 2025
Figure 45. Monoclonal Antibody
Figure 46. Bispecific Antibody
Figure 47. Fixed-dose Antibody Combination
Figure 48. Antibody Enzyme Combination
Figure 49. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Molecular Format (2021-2032)
Figure 50. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Molecular Format (2021-2032)
Figure 51. World Checkpoint Inhibitors for Treating Cancer Average Price by Molecular Format (2021-2032) & (US$/Unit)
Figure 52. World Checkpoint Inhibitors for Treating Cancer Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 53. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Dosage Form in 2025
Figure 54. Intravenous Liquid Concentrate
Figure 55. Intravenous Lyophilized Powder
Figure 56. Subcutaneous Ready-to-use Injection
Figure 57. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Dosage Form (2021-2032)
Figure 58. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Dosage Form (2021-2032)
Figure 59. World Checkpoint Inhibitors for Treating Cancer Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 60. World Checkpoint Inhibitors for Treating Cancer Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 61. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Application in 2025
Figure 62. Lung Cancer
Figure 63. Gastrointestinal Cancer
Figure 64. Genitourinary Cancer
Figure 65. Hepatobiliary Cancer
Figure 66. Gynecologic Cancer
Figure 67. Skin Cancer
Figure 68. Breast Cancer
Figure 69. Head and Neck Cancer
Figure 70. Head and Neck Cancer
Figure 71. World Checkpoint Inhibitors for Treating Cancer Production Market Share by Application (2021-2032)
Figure 72. World Checkpoint Inhibitors for Treating Cancer Production Value Market Share by Application (2021-2032)
Figure 73. World Checkpoint Inhibitors for Treating Cancer Average Price by Application (2021-2032) & (US$/Unit)
Figure 74. Checkpoint Inhibitors for Treating Cancer Industry Chain
Figure 75. Checkpoint Inhibitors for Treating Cancer Procurement Model
Figure 76. Checkpoint Inhibitors for Treating Cancer Sales Model
Figure 77. Checkpoint Inhibitors for Treating Cancer Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
